BR112012019351A2 - composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica. - Google Patents
composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica.Info
- Publication number
- BR112012019351A2 BR112012019351A2 BR112012019351A BR112012019351A BR112012019351A2 BR 112012019351 A2 BR112012019351 A2 BR 112012019351A2 BR 112012019351 A BR112012019351 A BR 112012019351A BR 112012019351 A BR112012019351 A BR 112012019351A BR 112012019351 A2 BR112012019351 A2 BR 112012019351A2
- Authority
- BR
- Brazil
- Prior art keywords
- carnitine
- propionyl
- prevention
- treatment
- active ingredients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10152363A EP2353596A1 (en) | 2010-02-02 | 2010-02-02 | Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency |
| US32253210P | 2010-04-09 | 2010-04-09 | |
| PCT/IB2011/000200 WO2011095882A1 (en) | 2010-02-02 | 2011-02-07 | Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012019351A2 true BR112012019351A2 (pt) | 2017-06-27 |
Family
ID=41820403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012019351A BR112012019351A2 (pt) | 2010-02-02 | 2011-02-07 | composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20110189152A1 (zh) |
| EP (2) | EP2353596A1 (zh) |
| CN (1) | CN102791263B (zh) |
| AU (1) | AU2011212153B2 (zh) |
| BR (1) | BR112012019351A2 (zh) |
| CO (1) | CO6551731A2 (zh) |
| DK (1) | DK2531189T3 (zh) |
| EA (1) | EA021107B1 (zh) |
| ES (1) | ES2487647T3 (zh) |
| IL (1) | IL221273A (zh) |
| MX (1) | MX2012008890A (zh) |
| NZ (1) | NZ600695A (zh) |
| PE (1) | PE20121700A1 (zh) |
| PL (1) | PL2531189T3 (zh) |
| PT (1) | PT2531189E (zh) |
| RS (1) | RS53515B1 (zh) |
| SG (1) | SG182323A1 (zh) |
| SI (1) | SI2531189T1 (zh) |
| UA (1) | UA107687C2 (zh) |
| WO (1) | WO2011095882A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2999934B1 (fr) * | 2012-12-21 | 2015-02-20 | Servier Lab | Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane |
| ES2656288T3 (es) * | 2013-12-05 | 2018-02-26 | Alfasigma S.P.A. | Composición útil para favorecer la fertilidad femenina |
| FR3019820B1 (fr) * | 2014-04-15 | 2017-07-21 | Peter Weyts | Composes de type flavonoides pour leur utilisation dans le traitement d'une pathologie du pied d'un mammifere ongule-composition pharmaceutique associee |
| CN104605451A (zh) * | 2015-01-31 | 2015-05-13 | 丁年生 | 一种防止毛细血管出血的玫瑰花饮料及其制备方法 |
| RU2704976C2 (ru) * | 2017-05-10 | 2019-11-01 | Общество с ограниченной ответственностью "Трейдсервис" | Флеботропная комбинированная фармацевтическая композиция |
| RU2705794C1 (ru) * | 2018-09-26 | 2019-11-12 | Общество с ограниченной ответственностью "Трейдсервис" | Комбинированная мягкая лекарственная форма для лечения геморроидальных заболеваний |
| RU2689409C1 (ru) * | 2018-11-21 | 2019-05-28 | Общество с ограниченной ответственностью "Трейдсервис" | Комбинированная мягкая лекарственная форма диосмина и троксерутина |
| IT202000003122A1 (it) * | 2020-02-17 | 2021-08-17 | Apharm Srl | Associazione di principi attivi e loro uso nel trattamento e/o nella prevenzione della insufficienza venosa |
| HUP2100299A1 (hu) | 2021-08-19 | 2023-02-28 | Keri Pharma Hungary Kft | Új gyógyászati kombináció alkalmazása krónikus vénás elégtelenség kezelésére |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2903558C2 (de) | 1978-02-03 | 1994-09-01 | Sigma Tau Ind Farmaceuti | Verwendung von L-Carnitin |
| IT1156852B (it) | 1978-07-10 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Procedimento industriale per la preparazione del d'canforato della l carnitinammide e del d canforato della d carnitinammide e sue applicazioni |
| IT1206954B (it) | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche |
| IT1142934B (it) * | 1981-11-06 | 1986-10-15 | Sigma Tau Ind Farmaceuti | Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene |
| CH662505A5 (it) * | 1985-04-30 | 1987-10-15 | Seuref Ag | Composizioni farmaceutiche ad azione protettiva vascolare. |
| JP2669146B2 (ja) | 1990-11-26 | 1997-10-27 | 富士電機株式会社 | 半導体素子の保護用ヒューズ |
| FR2710844B1 (fr) * | 1993-10-07 | 1995-12-29 | Bidel Christian Georges | Composition pour le traitement ou la prévention de l'herpès. |
| EP0793962B1 (en) | 1996-03-04 | 1999-12-08 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Medicament containing a carnitine derivative for treating arteriosclerosis obliterans |
| US5949786A (en) * | 1996-08-15 | 1999-09-07 | 3Com Corporation | Stochastic circuit identification in a multi-protocol network switch |
| IT1302863B1 (it) * | 1998-11-13 | 2000-10-10 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un |
| ITRM20020055A1 (it) * | 2002-02-04 | 2003-08-04 | Aldo Fassi | Sali metallici di carnitine, integratori dietetici/nutritivi che li contengono e kit dietetici per contrastare disturbi sessuali in soggetti |
| DE10240923A1 (de) * | 2002-09-02 | 2004-03-04 | Merck Patent Gmbh | Flavonoid-Derivate zur Ekzem-Behandlung |
| ITRM20030178A1 (it) | 2003-04-17 | 2004-10-18 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
| AT501682A1 (de) * | 2005-01-14 | 2006-10-15 | Hermine Dr Engl | Verfahren zur herstellung einer wirkstoffmischung |
| US20070087975A1 (en) | 2005-10-17 | 2007-04-19 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients |
| MX2007011002A (es) * | 2007-09-07 | 2009-03-09 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica. |
-
2010
- 2010-02-02 EP EP10152363A patent/EP2353596A1/en not_active Withdrawn
-
2011
- 2011-02-07 PL PL11709464T patent/PL2531189T3/pl unknown
- 2011-02-07 EP EP11709464.9A patent/EP2531189B1/en active Active
- 2011-02-07 PE PE2012001096A patent/PE20121700A1/es active IP Right Grant
- 2011-02-07 US US13/022,102 patent/US20110189152A1/en not_active Abandoned
- 2011-02-07 SG SG2012049011A patent/SG182323A1/en unknown
- 2011-02-07 EA EA201200786A patent/EA021107B1/ru not_active IP Right Cessation
- 2011-02-07 US US13/576,780 patent/US20130005670A1/en not_active Abandoned
- 2011-02-07 BR BR112012019351A patent/BR112012019351A2/pt active Search and Examination
- 2011-02-07 AU AU2011212153A patent/AU2011212153B2/en not_active Ceased
- 2011-02-07 MX MX2012008890A patent/MX2012008890A/es active IP Right Grant
- 2011-02-07 RS RSP20140448 patent/RS53515B1/en unknown
- 2011-02-07 ES ES11709464.9T patent/ES2487647T3/es active Active
- 2011-02-07 UA UAA201207518A patent/UA107687C2/ru unknown
- 2011-02-07 CN CN201180008020.8A patent/CN102791263B/zh active Active
- 2011-02-07 WO PCT/IB2011/000200 patent/WO2011095882A1/en active Application Filing
- 2011-02-07 DK DK11709464.9T patent/DK2531189T3/da active
- 2011-02-07 SI SI201130232T patent/SI2531189T1/sl unknown
- 2011-02-07 PT PT117094649T patent/PT2531189E/pt unknown
- 2011-02-07 NZ NZ600695A patent/NZ600695A/en not_active IP Right Cessation
-
2012
- 2012-06-20 CO CO12103267A patent/CO6551731A2/es not_active Application Discontinuation
- 2012-08-02 IL IL221273A patent/IL221273A/en not_active IP Right Cessation
-
2013
- 2013-09-19 US US14/031,555 patent/US9457037B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ600695A (en) | 2014-03-28 |
| AU2011212153A1 (en) | 2012-07-05 |
| EA201200786A1 (ru) | 2013-01-30 |
| WO2011095882A1 (en) | 2011-08-11 |
| US20110189152A1 (en) | 2011-08-04 |
| AU2011212153B2 (en) | 2016-08-04 |
| EP2353596A1 (en) | 2011-08-10 |
| PT2531189E (pt) | 2014-08-25 |
| IL221273A0 (en) | 2012-10-31 |
| EA021107B1 (ru) | 2015-04-30 |
| US20140018310A1 (en) | 2014-01-16 |
| SG182323A1 (en) | 2012-08-30 |
| ES2487647T3 (es) | 2014-08-22 |
| WO2011095882A8 (en) | 2012-08-02 |
| DK2531189T3 (da) | 2014-09-01 |
| US20130005670A1 (en) | 2013-01-03 |
| EP2531189B1 (en) | 2014-06-11 |
| SI2531189T1 (sl) | 2014-09-30 |
| CO6551731A2 (es) | 2012-10-31 |
| MX2012008890A (es) | 2012-08-31 |
| UA107687C2 (ru) | 2015-02-10 |
| PE20121700A1 (es) | 2012-12-22 |
| RS53515B1 (en) | 2015-02-27 |
| US9457037B2 (en) | 2016-10-04 |
| IL221273A (en) | 2015-07-30 |
| EP2531189A1 (en) | 2012-12-12 |
| PL2531189T3 (pl) | 2014-10-31 |
| CN102791263B (zh) | 2016-10-12 |
| CN102791263A (zh) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012019351A2 (pt) | composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica. | |
| CL2015001486A1 (es) | Composición que comprende agentes de control biológico. | |
| CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
| CL2015002519A1 (es) | Composiciones antimicrobiales y procedimientos de uso relacionados. | |
| BR112015001596A2 (pt) | composição para o tratamento de hiperlipidemia que compreende oxintomodulina. | |
| BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
| BR112013013402A2 (pt) | combinações de ingredientes ativos que compreendem piridiletilbenzamidas e outros ingredientes ativos | |
| CL2014001994A1 (es) | Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido. | |
| GT201500011A (es) | Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso | |
| BR112013016204A2 (pt) | composições de ingredientes ativos solúveis em gordura que contêm complexos de proteína vegetal-polissacarídeo de soja. | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| BR112012027279A2 (pt) | composições de emulsão farmacêutica com baixo teor de óleo que compreendem progestogênio | |
| BR112012006692A2 (pt) | composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas | |
| BR112013002685A2 (pt) | composições alimentícias para animais de estimação apresentando atividade antimicrobiana | |
| BR112012020719A2 (pt) | formulação herbicida método de tratamento de plantas com herbicida método de aumento da eficácia de uma formulação herbicida, e, uso de uma composição | |
| BR112012029746A2 (pt) | composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação | |
| CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
| EA201290373A1 (ru) | Синергическая противовирусная композиция и ее применение | |
| BR112017021527A2 (pt) | dentifrícios com base em cálcio para acentuar absorção de ingredientes ativos. | |
| CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
| BR112016007462A2 (pt) | fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite | |
| DK3466437T3 (da) | Middel til forebyggelse eller terapi af perinatale sygdomme for drøvtyggere | |
| EE201300004A (et) | Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks | |
| BR112015011759A2 (pt) | composição simbiótica e uso da mesma | |
| BR112015003824A2 (pt) | composto; método de tratamento de uma amiloidose em um indivíduo; composição farmacêutica; e método para tratar uma condição que é um membro selecionado da perda de memória, perda de cognição e uma combinação destas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ALFASIGMA S.P.A. (IT) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |